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LEARNING OBJECTIVES
After completing this course, the reader will be able to:
1. Discuss the significance of deletions and mutations of the EGFR gene in cancer cell growth and survival.
2. Describe the significance of the role of EGFR in malignant peripheral nerve sheath tumors, especially those
associated with neurofibromatosis 1.
3. Discuss the significance of why small molecule inhibitor therapy has been ineffectual in synovial sarcomas and
malignant peripheral nerve sheath tumors.
Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.comCME
ABSTRACT
Background. Synovial sarcomas (SnSrcs) and malig-
nant peripheral nerve sheath tumors (MPNSTs) are
rare mesenchymal tumors of adolescence and young
adulthood. Previous work from our laboratory has
demonstrated that SnSrcs express epidermal growth
factor receptor (EGFR) and human EGFR (HER)-2/
neu. The present study extends that work to examine the
expression of EGFR in MPNSTs and the characteriza-
tion of potential targets of the EGFR tyrosine kinase do-
main.
Methods. Tissue microarrays containing 48 cases of
SnSrc and 32 cases of MPNST were stained for EGFR,
EGFRvIII, and activated EGFR (pY1068-EGFR). Tu-
mor DNA was extracted from fresh and formalin-fixed,
paraffin-embedded tissue blocks and sequenced for ex-
ons 17–21 of EGFR and exon 2 of K-ras and b-raf.
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Results. Immunohistochemistry (IHC) demonstrated
that EGFR is expressed in a majority of SnSrcs and
MPNSTs (71% and 62.5%, respectively). EGFRvIII im-
munoreactivity was negative. IHC was weakly immunopo-
sitive for activated EGFR (18.7% and 3.1%, respectively).
Sequence analysis of the EGFR genomic DNA did not
demonstrate mutations in exons 17–21. No K-ras or b-raf
mutations were observed in either tumor type.
Conclusions. Expression of EGFR in SnSrcs and
MPNSTs with an intact EGFR/mitogen-activated protein
kinase pathway has been hypothesized to contribute to the
malignant potential of these tumors. Our study reveals the
absence of known activating mutations in EGFR, which
suggests that trials of small-molecule inhibitors would be
of little clinical benefit. A clinical study of treatment with
cetuximab is ongoing and may help elucidate whether
blockade of EGFR with antibodies is likely to be more
active. The Oncologist 2008;13:459–466
INTRODUCTION
Synovial sarcomas (SnSrcs) and malignant peripheral
nerve sheath tumors (MPNSTs) are rare mesenchymal tu-
mors of adolescence and young adulthood [1]. Gene-ex-
pression profiling has suggested that these two tumors are
similar and tend to cluster together in cluster analyses of mi-
croarray data [2, 3].
SnSrcs are malignant soft tissue tumors that account for
approximately 7%–8% of all malignant mesenchymal tu-
mors and tend to occur primarily in children and young
adults [4]. Morphologically, they are biphasic, with spindle
and epithelioid glandular cells, or monophasic, with a pure
spindle-cell pattern. The majority of tumors possess a spe-
cific chromosomal translocation, where the proximal part
of SYT (18q11) is translocated to the distal portion of one of
several duplicated SSX genes (most notably SSX1 and
SSX2) on the short arm of chromosome X (Xp11). The SYT/
SSX1 translocation is present in the majority (75%) of pa-
tients and is associated with a poor prognosis [5, 6]. The
SYT/SSX1 translocation is associated with both the biphasic
and monophasic patterns, whereas the SYT/SSX2 transloca-
tion is usually associated with only the sarcomatous (mono-
morphic) morphology.
Although surgery, radiotherapy, and adjuvant chemo-
therapy have improved the outcome of patients with local
disease, management of distant metastasis remains prob-
lematic. Local disease recurrence, large tumors, lack of dif-
ferentiation, older patient age, and pulmonary metastasis
are all poor prognostic factors. Accordingly, there is a need
for alternate therapies, including molecularly targeted
agents such as those recently developed against the receptor
tyrosine kinases (RTKs), such as imatinib for the treatment
of gastrointestinal stromal tumor (GIST) and erlotinib for
non-small cell lung cancer (NSCLC).
The MPNSTs account for approximately 5%–10% of all
soft tissue sarcomas; about one fourth to one half occur with
neurofibromatosis 1 (NF1) [7, 8]. Morphologically, most
MPNSTs resemble fibrosarcomas in their overall organiza-
tion, with certain modifications. Classically, the cells reca-
pitulate the features of the normal Schwann cells. The cells
have markedly irregular contours, and the nuclei are wavy,
buckled, or comma shaped. The cytoplasm stains lightly
and is usually indistinct. The cells can range from spindled
in shape to fusiform or even rounded, such that the lesion
can mimic a fibrosarcoma or even a round cell sarcoma [1].
Most MPNSTs are high-grade sarcomas, with a high
likelihood of producing local recurrence and distant metas-
tasis. In large series, the local recurrence rate varies in the
range of 40%–65% and the metastatic rate is in the range of
40%– 68% [8 –10]. The 5-year survival rate based on a
study of 134 patients with tumors from all sites was 52%
[8]. Treatment with extensive surgery often coupled with
adjuvant radiation or chemotherapy has improved survival.
Prognostic factors in this disease include the size of the le-
sion, location, stage, grade, status of surgical margins,
necrosis, and use of adjuvant radiation [9, 10]. In a mul-
tivariate analysis, the status of surgical margins and a his-
tory of irradiation emerge as independent prognostic
variables.
MPNSTs arising in patients with NF1 syndrome are
known to have aggressive clinical characteristics. The ma-
jority of patients have advanced disease at the time of diag-
nosis and the overall outcome of treatment is discouraging.
A recently published large Italian and German series of
children and adolescents with MPNST clearly demon-
strated the poor survival rates of NF1 patients in compari-
son with cases without NF1, with 5-year progression-free
survival (PFS) and overall survival rates of 19% and 32% in
NF1 cases, respectively, versus 42% and 55% in non-NF1
cases, respectively [11]. Although some previous studies
reported similar outcomes in NF1 and non-NF1 patients,
most published adult MPNST series emphasize the worse
prognosis of NF1 patients [7–9, 12, 13]. MPNSTs arising in
NF1 cases appear more chemoresistant, with reported re-
sponse rates in the Italian and German series of 17% in NF1
cases versus 55% in non-NF1 cases [11], suggesting bio-
logical differences between MPNST patients with and
without NF1. A recent series by Ferrari et al. [14] confirmed
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this finding, with only 2 of 16 cases of MPNSTs arising in
NF1 patients achieving partial responses to chemotherapy.
Previous work from our laboratory has demonstrated
that SnSrcs express the RTKs epidermal growth factor re-
ceptor (EGFR) and human EGFR (HER)-2/neu [15]. The
present study extends this work to examine the expression
of EGFR in MPNSTs, the role of the activated EGFR/
mitogen-activated protein kinase pathway in both tumor
types, and the characterization of potential targets of the
EGFR tyrosine kinase domain for which small-molecule in-
hibitors are available.
The human EGFR (ErbB) family of RTKs is an impor-
tant group of mediators responsible for cell proliferation,
survival, adhesion, migration, and differentiation [16]. The
family comprises four distinct receptors: EGFR, HER-2,
HER-3, and HER-4. EGFR, HER-3, and HER-4 are stimu-
lated by a variety of ligands, whereas no known ligand has
been identified for HER-2/neu. With the exception of
HER-3, which lacks tyrosine kinase activity, all are trans-
membrane RTKs [17]. Once activated by their respective
ligands, they rapidly dimerize either as homodimers or het-
erodimers and exert their biologic activity through several
different signal transduction pathways. EGFR is expressed
in a variety of neoplasms, including cervical, ovarian, blad-
der, and esophageal carcinomas. Deletions of the extracel-
lular domain of EGFR also have an activating effect on the
receptor, providing the cells that express these truncated re-
ceptors with a proliferative advantage [18].
MATERIALS AND METHODS
Tumors and Patients
Fresh and formalin-fixed, paraffin-embedded (FFPE) tis-
sue blocks of SnSrcs and MPNSTs were obtained from the
files of the Department of Pathology, University of Michi-
gan Medical Center, Ann Arbor, MI. Institutional review
board approval was obtained and the diagnosis was con-
firmed by morphology. The diagnoses of SnSrc and
MPNST were defined according to the recently published
World Health Organization criteria [19]. After pathological
review, tissue microarrays were constructed from the most
representative area using the methodology of Nocito et al.
[20]. These are the same patients described in our recently
published cluster analysis paper [21] and HER-2/neu and
EGFR expression manuscript [15].
Clinical data on all patients were obtained from the can-
cer registry and included age, gender, tumor type, date of
diagnosis, dates and modalities of treatments received, time
to recurrence, time to death or loss to follow-up, and vital
status. Descriptive data were reviewed, and survival data
were analyzed using the Kaplan–Meier method. All statis-
tical analyses were performed using the STATA 9.2 statis-
tical package (StataCorp, College Station, TX).
Immunohistochemical Staining
Immunohistochemical (IHC) staining was performed on
the Dako Autostainer (Dako, Carpinteria, CA) using Dako
labeled streptavidin biotin (LSAB) and diaminobenza-
dine (DAB) as the chromogen. Deparaffinized sections of
formalin-fixed tissue at 5-m thickness were labeled with
several antibodies as detailed in Table 1. Appropriate neg-
ative (no primary antibody) and positive (breast carcinoma)
controls were stained in parallel with each set of tumors
studied. The immunoreactivity was scored by a three-tier
modification of the normal grading scheme previously de-
scribed by Wang et al. [22]. Our three-tier system assigns a
score of zero to negative immunoreactivity, a low score
(1) to diffusely weak or focally strong immunoreactivity,
and a high score (2) to diffusely strong immunopositivity.
DNA Extraction and Mutational Analysis
DNA was extracted from three 5-m thick sections of each
SnSrc and MPNST FFPE specimen using a Nucleon HT
DNA extraction kit (Amersham Biosciences, Piscataway,
NJ) according to the manufacturer’s instructions. Genomic
exons 17–21 of the EGFR gene, exon 2 of the cK-ras gene,
and exon 2 of the b-raf gene were separately amplified ac-
cording to the methods of Yantiss et al. [23] and detailed in
Table 2. Amplicons were purified using a Wizard SV PCR
clean-up kit (Promega, Madison, WI) and sequenced di-
rectly within the University of Michigan Medical Center
DNA sequencing core using an ABI 377 DNA sequencer
Table 1. Antibodies used in this study
Antibody Manufacturer Concentration Epitope retrieval Detection
EGFR Zymed 1:50 Protease K, 10 minutes LSAB
pY-EGFR (Y1086) Zymed 1:200 Trypsin, 10 minutes, 37°C Polymer HRP
EGFRvIII Zymed 1:100 HIER, pH 6 Polymer HRP
Abbreviations: EGFR, epidermal growth factor receptor; HIER, heat-induced epitope retrieval; HRP, horseradish
peroxidase; LSAB, labeled streptavidin biotin.
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(ABI, Foster City, CA). Chromatograms were downloaded
directly to CodonCode Aligner software (v1.4.4, Codon-
Code Corp., Dedham, MA), and the sequence was com-
pared with the reference sequence downloaded from the
National Center for Biotechnology Information. The refer-
ence sequence numbers are NM_005228 for EGFR,
NM_033360 for cK-ras, and NM_004333 for b-raf.
RESULTS
Clinicopathologic Data
Forty-eight specimens of SnSrc from 35 patients were stud-
ied. The average age of the patients was 33 years (range,
7–70), with a male-to-female ratio of 1:1.2. There were 29
patients with the SSX1 translocation and six with the SSX2
translocation. No patients with the SSX4 translocation were
observed.
Thirty-two cases of MPNST from 28 patients were used
for this study. Ten patients had documented NF1 by stan-
dard clinical criteria, although mutational analysis for NF1
was not performed. The average age was 38.6 years (range,
5–76) with a male-to-female ratio of 1:1.15.
Expression of EGFR, EGFRvIII, and
Phosphorylated EGFR in SnSrc and MPNST
by IHC
IHC analysis of 48 SnSrc specimens representing primary
and metastatic lesions using the anti-EGFR polyclonal an-
tibody demonstrated the characteristic membranous stain-
ing associated with membrane-bound tyrosine kinases in 34
specimens (71%). The majority had weak staining (1);
only two samples had strong staining (2), similar to pos-
itive controls (Fig. 1A). IHC analysis of 32 MPNST speci-
mens demonstrated EGFR expression in 20 specimens
(62.5%), with six specimens staining strongly positive
(19%) (Fig. 2A), while the rest were weakly positive. All
positive and negative IHC controls were appropriate.
Figure 1. Immunohistochemical stain for epidermal growth
factor receptor (EGFR) and its activated form (pY1068-EGFR) in
two cases of synovial sarcoma. (A): Mixed epithelial–spindle cell
pattern of SYT/SSX1 translocation synovial sarcoma demonstrat-
ing diffuse strong immunoreactivity for EGFR (anti-EGFR,
avidin-biotin peroxidase complex/hematoxylin; original mag-
nification 400). (B): Diffuse immunoreactivity for pY1068-
EGFR in a spindle-cell synovial sarcoma with SYT/SSX1
translocation (anti-pY1068-EGFR, avidin-biotin peroxidase
complex/hematoxylin; original magnification200).
Table 2. Primer sequences and reaction conditions
Gene Exon Forward primer Reverse primer
Annealing
temperature
Amplicon
size (bp)
EGFR 17 TCCTTGTTCCTCCACCTCAT TATGTATCTAACATACACAAC
TGCTAAT
55 270
EGFR 18 GCTGAGGTGACCCTTGTCTC ACAGCTTGCAAGGACTCTGG 55 246
EGFR 19 CCCAGTGTCCCTCACCTTC CCACACAGCAAAGCAGAAAC 55 239
EGFR 20 TTCTGGCCACCATGCGA CCGTATCTCCCTTCCCTGATTA 55 258
EGFR 21 TGATCTGTCCCTCACAGCAG TCAGGAAAATGCTGGCTGAC 55 231
cK-ras 2 GGCCTGCTGAAAATGACTGA GTCCTGCACCAGTAATATGC 60 162
b-raf 2 TGCACAGGGCATGGATTACTTA TTCTGGTGCCATCCACAA 52 190
Abbreviation: EGFR, epidermal growth factor receptor.
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IHC was next performed with a polyclonal antibody
specific to the phosphorylated form of EGFR (pY1068-
EGFR). Nine of 48 (18.7%) SnSrc specimens demonstrated
positive membranous staining (Fig. 1B), while only one of
32 MPNSTs (3.1%) was positive (Fig. 2B). IHC analysis
for EGFRvIII was performed on MPNSTs and was
uniformly negative, suggesting the absence of this modifi-
cation of the receptor in MPNSTs.
Mutational analysis of the EGFR genomic DNA dem-
onstrated no evidence of point mutations in the exons eval-
uated. However, a presumptive 20-base pair insertion was
seen in exon 18 in 17 of 48 samples of SnSrc (14.5%) and 8
of 32 MPNSTs (25%). No K-ras mutations in codons 12 or
13 or in exon 2 of the b-raf gene were identified in either
tumor type.
Survival by EGFR, Phosphorylated EGFR, and
EGFRvIII Status
Survival data were analyzed using the Kaplan–Meier
method. Patients with SnSrcs that expressed EGFR, phos-
phorylated EGFR, or EGFRvIII did not have any statisti-
cally significant difference in time to first recurrence or
death when compared with patients that lacked expression.
Similarly, there was no difference in the time to recur-
rence or survival time in patients with MPNSTs that had
positive expression of EGFR as compared with those with-
out EGFR expression. The presence or absence of phos-
phorylated EGFR expression did not correlate with disease
outcome in MPNST.
DISCUSSION
In an earlier report, we examined the expression of the
EGFR and HER-2/neu genes in 38 samples of SnSrc repre-
senting 30 patients using IHC and molecular methods. We
demonstrated that EGFR and HER-2/neu were expressed in
the majority of cases, albeit at relatively low levels [15].
In this report, we extend our previous findings on the
expression of EGFR in SnSrcs to examine the expression of
the activated form of EGFR (phosphorylated EGFR). We
also report the largest series of MPNST tissue examined for
the expression of EGFR, its phosphorylated form p-EGFR,
as well as the prevalence of the mutated form EGFRvIII.
Deletions of the extracellular domain of EGFR have an ac-
tivating effect on the receptor, providing the cells that express
the truncated receptors with a proliferative advantage [24].
The most common truncated receptor is the variant III
EGFR deletion mutant (EGFRvIII), which contains an in-
frame deletion of exons 2–7 from the extracellular domain
and is commonly observed in glioblastomas. EGFRvIII has
recently been found to be present in a small percentage
(5%) of human NSCLCs [25]. Murine data confirm that
overexpression of EGFRvIII is oncogenic in lung tissue. In
addition, the abrogation of EGFRvIII expression by with-
holding doxycycline causes regression of the lung tumors,
showing that these tumors are dependent on the activated
EGFR pathway [26]. It has also been shown that HKI-272,
an irreversible inhibitor that covalently binds to the EGFR
kinase domain cleft, is effective in the treatment of EGFRvIII-
dependent mouse lung tumors. Gefitinib and erlotinib also
inhibit the growth of cells harboring EGFRvIII mutations,
although at much higher concentrations than HKI-272. It is
reasoned that this partial activity may provide an explana-
tion for the reported response seen with erlotinib in a small
percentage of squamous cell lung carcinomas [25].
Figure 2. Immunohistochemical stain for epidermal growth
factor receptor (EGFR) and its activated form (pY1068-
EGFR) in two cases of malignant peripheral nerve sheath tu-
mor (MPNST). (A): MPNST demonstrating diffuse strong
immunoreactivity for EGFR (anti-EGFR, avidin-biotin per-
oxidase complex/hematoxylin; original magnification400).
(B): Diffuse positive immunoreactivity for pY1068-EGFR in
an MPNST (anti-pY1068-EGFR, avidin-biotin peroxidase
complex/hematoxylin; original magnification200).
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Our findings have a direct clinical implication because ty-
rosine kinase inhibitors are already being examined in early
clinical trial settings for activity in SnSrcs and MPNSTs.
While this approach appears to be warranted in SnSrcs given
the high expression of EGFR, MPNSTs may be less amenable
to show therapeutic benefit because they have a lower preva-
lence of EGFR expression and lower activation.
Preclinical evidence has suggested a central role for
EGFR in the tumorigenesis of MPNSTs, particularly asso-
ciated with NF1. As early as 1992, Basu et al. [27] provided
evidence that Ras proteins in malignant tumor cell lines
from patients with NF1 are in a constitutively activated
state. These cells were shown to contain p21ras and
p120GAP that are both functionally wild type, but barely
any functional NF1 protein. The authors concluded that
NF1 protein is normally essential for correct negative reg-
ulation of Ras proteins in the cell, and thus acts as a tumor
suppressor whose product acts upstream of Ras [27].
DeClue et al. [28] provided additional evidence for the
role of the EGFR pathway when they used immunoblotting,
Northern analysis, and IHC to demonstrate that each of
three MPNST cell lines from NF1 patients expressed the
EGFR, as did seven of the seven other primary MPNSTs, a
non-NF1 MPNST cell line, and the S100 cells from each
of nine benign neurofibromas. Furthermore, transformed
derivatives of Schwann cells from NF1–/– mouse embryos
also expressed EGFR. All the cells or cell lines expressing
EGFR responded to EGF by activation of downstream sig-
naling pathways. The authors concluded that EGFR expres-
sion may play an important role in NF1 tumorigenesis and
Schwann cell transformation. This hypothesis was further
tested by demonstrating that growth of NF1 MPNST lines
and the transformed NF1/ mouse embryo Schwann
cells was greatly stimulated by EGF in vitro and could be
blocked by agents that antagonize EGFR function [28].
EGFR was also found to be expressed in 23 of 24 cell lines
derived from malignant soft tissue sarcomas from Nf1:p53
compound heterozygous mice [29]. EGFR gene amplification
is also observed in MPNSTs [30]. Ling et al. [31] showed that
expression of EGFR in transgenic mouse Schwann cells elicits
features of neurofibromas such as Schwann cell hyperplasia,
excess collagen, mast cell accumulation, and progressive dis-
sociation of non–myelin-forming Schwann cells from axons.
Mating EGFR transgenic mice to Nf1 hemizygotes did not en-
hance this phenotype. Genetic reduction of EGFR in Nf1(/
):p53(/) mice that develop sarcomas significantly
improved survival. Thus, gain- and loss-of-function experi-
ments support the relevance of EGFR to peripheral nerve tu-
mor formation [31].
A xenograft model for MPNST was developed by Mahl-
ler et al. [32], and the effect of EGFR inhibition with erlo-
tinib was tested. When grown in the presence of erlotinib,
the MPNST cell lines STS26T and S462 showed lower ex-
pression of proangiogenic genes and demonstrated antipro-
liferative effects. s.c. tumors treated with erlotinib daily, for
five consecutive days, illustrated a lower vascular density
(p .01), and analysis of vessel size distribution showed a
trend toward fewer small vessels within erlotinib-treated
tumors. These results suggest that erlotinib has antiprolif-
erative and antiangiogenic effects against MPNSTs [32].
The role of EGFR in MPNST development was compel-
ling in preclinical settings and led to the evaluation of ty-
rosine kinase inhibitors in patients with MPNSTs. Erlotinib
was given at 150 mg/day in a phase II study of the South-
west Oncology Group in metastatic or unresectable
MPNSTs [33]. Twenty-four patients were enrolled over 22
months, from 13 institutions. The median age was 45.3
years; 50% had neurofibromatosis. At enrollment, 15 had
performance status scores of 0–1, 18 had metastatic dis-
ease, and 19 had unresectable disease. Twenty patients
were evaluable for response: one had stable disease after
first evaluation and 19 had no response. The median PFS
time observed was 2 months. Fourteen patients have died;
the median overall survival time was 4 months. Because no
objective responses were observed in the first stage of the
study (designed as a Simon two-stage trial), it was closed to
further accrual.
While our findings in MPNST are consistent with the
reported literature, we still found only 62% of tumors to ex-
press EGFR. But, more importantly, the downstream effect
of EGFR activation, namely, phosphorylation, was present
in only one tumor (3.1%), suggesting that, despite the ex-
pression of EGFR, this pathway does not appear to be con-
stitutively active and hence is not necessarily driving the
malignant machinery of the cell. This is more consistent
with the lack of a clinical benefit of EGFR tyrosine kinase
inhibition in MPNST. Furthermore, we have demonstrated
the absence of mutated forms of EGFR, which suggests that
a monoclonal antibody approach to EGFR inhibition may
be more effective in this tumor type. This approach war-
rants preclinical and/or clinical evaluation of anti-EGFR
monoclonal antibodies in the treatment of MPNST. In fact,
an ongoing trial of cetuximab at the University of Michigan
is open to patients with SnSrcs and MPNSTs as well as
other soft tissue and bony sarcomas.
The first report of EGFR expression in SnSrc was in
1985, when an immunocytochemical study of EGFR in 35
human soft tissue sarcomas showed particularly strong
staining in one epithelioid sarcoma and in the spindle-cell
component of an SnSrc [34]. Subsequently, Barbashina et
al. [35] reported that 13 of 19 SnSrcs (68%) were immuno-
reactive with EGFR. Also, 10 of 19 tumors (52%; seven
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monophasic and three biphasic) showed positive cytoplas-
mic and membranous staining with HER-2/neu (Hercep-
Test, Dako). However, cellular expression of HER-2/neu
was independent of EGFR positivity and showed no asso-
ciation with the proliferative activity of the tumors [35].
The expression of EGFR was examined in a cohort of 13
SnSrc patients. All specimens showed strong diffuse or fo-
cal EGFR expression. No amplifications of the EGFR gene
were found. In contrast, several point mutations were iden-
tified in exons 18–21 of two SnSrcs. Whereas one of these
tumors carried only a synonymous mutation, two missense
mutations in exons 19 and 21 of the EGFR gene (P733S and
A840 T, respectively) could be demonstrated in the second
sample. The authors concluded that strong EGFR expression
in SnSrcs is unrelated to gene amplification, and that the exis-
tence of mutations in the tyrosine kinase domain of the EGFR
gene in a small subset of SnSrcs suggests that only few patients
may benefit from tyrosine kinase inhibitor therapy [36].
Terry et al. [37] assessed the effect of gefitinib on two
SnSrc cell lines (monolayer Fuji and SYO-1). The gefitinib
50% inhibitory concentration was 265.1mol/l for Fuji and
266.4 mol/l for SYO-1. These concentrations are signifi-
cantly higher than those described to inhibit the prolifera-
tion of gefitinib-sensitive cell lines. Activating mutations in
EGFR affecting the kinase domain have recently been iden-
tified to bestow sensitivity to gefitinib in NSCLC. Similar
sensitizing mutations in exons 18, 19, and 21 of EGFR were
sought in each SnSrc cell line and 16 archival SnSrc tumor
specimens that strongly expressed the EGFR protein. How-
ever, no such mutations were found, consistent with our
findings [37].
Small-molecule tyrosine kinase inhibitors that target
EGFR have been used to treat patients with SnSrc. In a
phase II European Organization for Research and Treat-
ment of Cancer trial of second-line treatment of patients
with metastatic or locally advanced SnSrc, gefitinib was
given at 500 mg/day until progression or intolerance. The
primary endpoint was the PFS rate at 3 months. Forty-eight
patients were included, 27 (56%) men and 21 (44%)
women, with a median age of 42 years (range, 19 – 66).
Metastatic sites were lung in 92% and soft tissue or lymph
nodes in 42% of the patients. Thirty-seven patients were
evaluable for the primary endpoint, with a median treat-
ment duration of 11 weeks (range, 2–25). There were no ob-
jective responses reported. Seven (18%) patients achieved
stable disease as their best response. At 3 months, five of the
39 (13%) evaluable patients achieved PFS; the 6- and 12-
month PFS rates were 10% and 3%, respectively [38].
The role of the EGFR pathway has been of great scien-
tific interest and, more importantly, offers great potential
for improving clinical outcomes in patients with various
malignancies. The first member of the Erb family whose in-
hibition has shown impressive clinical activity was HER-2/
neu with the advent of trastuzumab in the treatment of
breast cancer. The monoclonal antibody approach to EGFR
has also found application in head and neck cancer,
NSCLC, and colon cancer. Small-molecule tyrosine kinase
inhibitors have been quite effective in a subset of patients
with EGFR mutations in NSCLC. These findings have the
potential of being transposable to the treatment of soft tis-
sue sarcomas. Soft tissue tumors are rare, thus limiting the
feasibility of large, randomized, phase III trials that allow
detection of small but clinically significant therapeutic im-
provements. Hence, there is value in building on preclinical
findings and the experience obtained from other tumors to
guide therapy in soft tissue tumors. Such an approach has
met monumental success in the therapy of GISTs with ima-
tinib. Our results support the role of EGFR in the carcino-
genesis of SnSrcs, but the lack of mutations may explain the
absence of a clinical benefit of tyrosine kinase inhibitors.
Similarly, the role of EGFR appears to be of less value in
the carcinogenesis of MPNST, because we found a low
prevalence of its activated form. The absence of EGFRvIII
mutations in both tumor types suggests that EGFR blockade
using a monoclonal antibody may offer the optimal ap-
proach for targeting this pathway in SnSrcs and MPNSTs.
The absence of any correlation between the expression
of EGFR pathway proteins and clinical outcome, as well as
the lack of observed clinical benefit with approaches de-
signed to abrogate this pathway, indicate that translating
laboratory findings into clinically oriented interventions
needs to happen only after careful examination of all avail-
able data and thorough evidence for the role of this pathway
in each specific tumor type has been obtained.
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